Day: August 17, 2023

Frontline plc.’s preliminary second quarter 2023 results will be released on Thursday August 24, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q2 2023 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.               Frontline plc Q2 2023 Conference Call A Q&A session will be held after the teleconference/webcast....

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter...

Revenue up 18% Y/Y to $116.7 Million, Excluding Discontinued Operations Company Delivers Record Adjusted EBITDA1 of $29.4 Million, up 78% Y/Y, 12% Sequentially, with Adjusted EBITDA Margin of 25% GAAP Loss from Operations Improved 81% Y/Y, 79% Sequentially to $(4.5) Million, Excluding Discontinued Operations MIAMI, Aug. 17, 2023 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the second quarter ended June 30, 2023. Unless otherwise noted, all results are presented in U.S. dollars. The following financial measures are reported as results from continuing operations due to the sale of the Company’s business in Arizona in March 2023, which are reported as discontinued operations....

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023 Bristol Myers Squibb exercised first opt-in into 2019 cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment Cash and cash equivalents as well as other financial assets not including the recent equity investment by Bristol Myers Squibb amount to $377.7 million1 (€347.6) as of June 30, 2023; updated projected cash runway is late 2025Tuebingen,...

9M 2022/23Interim financial results, 9M 2022/231 October 2022 – 30 June 2023 Coloplast delivered Q3 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 4% to 6,108 millionOrganic growth rates by business area: Ostomy Care 8%, Continence Care 9%, Voice and Respiratory Care 9%, Wound and Skin Care 4% (Wound Care 5%), and Interventional Urology 7%. Continued good momentum across regions in Chronic Care. China Ostomy Care posted double-digit growth, reflecting a lower baseline last year and fully normalised hospital access and level of procedural volumes. Strong quarter in Continence Care, with solid contribution from all product categories, including Collecting Devices where backorders have been resolved. Continued solid momentum in Voice and Respiratory Care, driven by both the laryngectomy and tracheostomy businesses. Growth...

Adjusted EBITDA significantly rebounded by 137%, and Adjusted EBITDA Margin doubled, in Q2 2023 compared to Q1 2023; Company expects further improvement to Adjusted EBITDA and Adjusted EBITDA Margin in H2 2023 vs. H1 2023 Generated significant programmatic revenue and CTV revenue in Q2 and H1 2023, driven by strategic investments and product development in Company’s core growth drivers Rebranded products and platforms as Nexxen, successfully simplifying the value proposition of the Company’s horizontal technology ecosystem, while driving greater customer adoption of multiple solutions and better positioning the Company to accelerate future revenue growth Completed the integration of Amobee following consolidation of Tremor Video and Amobee DSPs into the significantly enhanced Nexxen DSP, further strengthening the Company’s comprehensive...

Revenues for the Second Quarter Increased by 3% (or 9.1% on a constant currency basis) Year Over Year to a second-quarter record-breaking $655.4 Million with Net Income for the Second Quarter reaching $17.0 million OR YEHUDA, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its results for the second quarter and six month-period ended June 30, 2023. Financial Highlights for the Second Quarter Ended June 30, 2023Consolidated revenues for the second quarter ended June 30, 2023 increased by approximately 2.9% to a second-quarter...